Linemycin D nanoparticles for the treatment of acute myeloid leukemia
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Tiziana, a biotech company focused on innovative therapies for inflammation, autoimmune and infectious diseases, recently announced that it had acquired all of rasna Pharmaceuticals' intellectual property rights in line-dinD nanoparticle formulations under an asset purchase agreement to expand its product line for an initial $120,000 advanceAct D is an antibiotic drug originally approved in the United States in 1964 for the treatment of infectious diseasesThe antibiotic was later shown to be anticancer in 1974Since then, the drug has been used to treat various types of cancer, including transverse fibroids, Ewing sarcoma, nourishing cell tumors and testicular cancerThe drug is listed in the World Health Organization's Essential Medicines list as one of the most effective drugs required in the health systemFalini et alhave reported in the New England Journal of Medicine that Act D's intravenous administration can be used to treat acute myeloid leukemia (AML) that carries a mutation in the NPM1 geneRecent studies have also shown that Act D is an effective inhibitor of RNA synthesis and may have the potential to treat patients with COVID-19However, the drug is administered intravenously (IV) and may become highly toxic in the first few hours after administration due to high Levels of Cmax in the bloodAct D nanoparticle preparations allow act D to release slowly and pre-regulate Cmax in the blood to the desired level
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
